Trader's the last time we brought you this alert! It was $1.71!!
On July 1 st NNVC was at $1.71 and we had a little rally that day but more importantly we noted and asked this question:
Is this stock heading back to its highs??
It was not too long ago that NNVC broke $3.00 and based on the recent run that this stock is having can we see those highs again???
Take a look at the 3 month chart
The volume and the price of the stock has been heating up over the last few weeks!
There is no time like the present to put this stock back on your radar!!!
Full Report Below
A unique technology platform to fight deadly viruses may soon put little-known biotech company NNVC on the map!
Greetings Investors,
If the pandemic taught us anything, it's just how important antiviral medicines are!
Antiviral medications can help your immune system fight back by helping stop the virus from multiplying in your body. This enables you to recover quickly.
The success of penicillin led to an explosion in the development of antibacterials. Which makes one wonder, where is the game-changer for viruses?
One underfollowed NYSE-traded company called NanoViricides, Inc. (NYSE: NNVC) may have that game-changing answer!
NNVC has seen some northward movement in recent days and should be high on your radar.
Who is NNVC?
NanoViricides is a development stage company that is creating special-purpose nanomaterials for antiviral therapy. The Company's novelnanoviricide® class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. Additionally, nanoviricides mimic the host-side features that the viruses continue to require despite mutations, and therefore the viruses would be highly unlikely to escape the nanvoricide drugs.
The company is on a solid footing to revolutionize the treatment of antiviral infections with antiviral nanoviricides!
What are nanoviricides?
NNVC's anti-viral therapeutics, which it calls "nanoviricides®" are designed to appear to the virus-like the native host cell surface to which it binds.
Since these binding sites for a given virus do not change despite mutations and other changes in the virus, the company believes that its drugs will be broad-spectrum, i.e. effective against most if not all strains, types, or subtypes, of a given virus, provided the virus-binding portion of the nanoviricide is engineered appropriately.
Viruses would not be able to escape the nanoviricide by viral mutations since they continue to bind to the same cellular receptor and thus would be captured by the nanoviricide. Virus escape by mutations is a major problem in the treatment of viral diseases using conventional drugs.
therefore the viruses would be highly unlikely to escape the nanvoricide drugs.
Lead candidate NV-387:
NNVC's lead candidate NV-387 could revolutionize antiviral treatment the same way antibiotics did against bacteria!
Susceptible viruses CANNOT escape NV-387, even as they continue to evolve in the field, enabling NNVC to anticipate that nanoviricide drugs could have many decades-long "life of service."
No matter how much the virus changes, it continues to use the same host-side signature to bind to and cause infection in the hosts, and thus the nanoviricide would be anticipated to continue to be effective.
Thus NV-387 and other antiviral drugs designed on the nanoviricides platform can be expected to have a long duration of effective usability against the target viruses, reaching into several decades, similar to antibiotics, but in stark contrast with current antiviral approaches.
An antiviral drug such as NV-387 if found to be effective in human clinical studies would be a highly desirable drug globally. It would enable the treatment of patients as soon as they present to the physician with a viral disease without waiting for a test to identify which viral infection it is.
This is reminiscent of how antibiotics are prescribed, without specific infectious agent identification, relying on the ultra-broad-spectrum of antibacterial activity.
NV-387 to fight RSV, Covid, and other viruses:
NV-387 was substantially superior to remdesivir in coronavirus infections, using a model for SARS-CoV-2 (COVID) virus. The company believes that NV-387 continues to be one of the most active antiviral drugs against multiple coronaviruses, and that it is a viable clinical candidate for drug development to treat COVID, Long COVID, as well as potentially MERS, SARS, and seasonal coronavirus infections.
NV-387 was substantially superior to the three approved drugs, namely Tamiflu®, Rapivab® , and Xofluza® against an Influenza H3N2 lethal lung viral infection study, as previously reported. We believe that NV-387 is expected to possess strong antiviral activity against H5N1 "Bird Flu" as well, given that H5N1 viruses are known to bind to heparan sulfate proteoglycans, and based on the observed broad-spectrum activity of NV-387.
NV-387 was at least as good as TPOXX® in a model animal study for the development of Smallpox/Mpox drugs, in two different ways of acquiring infection, as reported earlier.
NNVC has also found that NV-387 is capable of completely curing a lethal RSV lung virus infection in animals, leading to the indefinite survival of the animals, as reported recently. There is no cure for RSV, and no approved drug for the treatment of RSV infection other than the toxic last-resort drug ribavirin!!
This means a safe and effective treatment remains an unmet medical need and offers this company an incredible market opportunity. NV-387 may be a candidate for the $1.8 Billion to $8 Billion annual market size to treat RSV infection, as estimated by GrowthPlus Reports.
In Summary….
Nanoviricides could be as revolutionary as antibiotics and do not rely on immune systems making them great for seniors and children!
NNVC's lead drug candidate NV-387 is aimed to treat RSV, Covid-19, Long Covid, Influenza, Bird Flu H5N1, and other respiratory viral infections.
The success of penicillin led to an explosion in the development of antibacterials that use the same mechanism of action and provide additional benefits, stronger activity against certain bacteria, and oral administration amongst them.
The world continues to use amoxicillin to treat most pediatric and adult bacterial infections to this day, some 65 years since its discovery in 1958! This durability is a direct result of the fact that most of the bacteria it attacks have not escaped the drug and have remained susceptible even after such a long time of common use.
But what about viruses? There is a significant unmet medical need for a broad-spectrum antiviral drug that is effective and useable in all segments of the population.
In pandemic preparedness and awareness, NNVC is standing out as a crucial biotech stock to keep your eyes on!
